Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).

Authors

Mario Campone

Cancer Institute of the West (ICO), Centre René Gauducheau, Medical Oncology Department, Saint-Herblain, France

Mario Campone , Luca Gianni , Javier Cortes , Thaddeus Beck , Julieann Miller , Peng Chen , Abderrahim Fandi , Jasgit C. Sachdev

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).

First Author: Charles Geyer

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER⁺ HER2^- metastatic breast cancer.

First Author: William John Gradishar

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

Randomized phase II open-label study of abiraterone acetate (AA) plus low-dose prednisone (P) with or without exemestane (E) in postmenopausal women with ER+ metastatic breast cancer (MBC) progressing after letrozole or anastrozole therapy.

First Author: Joyce O'Shaughnessy

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN).

First Author: Mothaffar F. Rimawi